Table 2 Study treatments, outcomes, and hemodynamic measurements
Reference | Treatment | n | Control group mortality | Study group mortality | Blood pressure goal | Other hemodynamic goals |
|---|---|---|---|---|---|---|
Tuchsmidt and colleagues [12] | Elevation of cardiac output with dobutamine and fluids | 51 | 18/25 (72%) | 13/26 (50%) | SBP > 90 mmHg | Treatment group: PAOP ≥ 15 mmHg and CI ≥ 6 l/min/m2; control group: CI ≥ 3 l/min/m2 |
Peake and colleagues [10] | N-acetyl-cysteine | 20 | 5/10 (50%) | 9/10 (90%) | SBP > 90 mmHg | CI ≥ 4 l/min/m2; PAOP 15–18 mmHg |
Bollaert and colleagues [11] | Supraphysiologic hydrocortisone | 40 | 12/19 (63%) | 7/21 (32%) | SBP > 90 mmHg | Â |
Spapen and colleagues [19] | N-acetyl-cysteine | 22 | 4/10 (40%) | 5/12 (41.6%) | MAP > 65 mmHg | CI > 4 l/min/m2 |
Alia and colleagues [18] | Maximizing of oxygen delivery with dobutamine | 63 | 21/32 (65.6%) | 23/31 (74.5%) | MAP > 60 mmHg | PAOP 12–15 mmHg; treatment group: DO2I > 600 ml/min/m2; control group: DO2I > 330 ml/min/m2 |
Boldt and colleagues [15] | Heparin | 56 | 11/28 (39.2%) | 10/28 (35.7%) | MAP > 65 mmHg | CVP 12–15 mmHg |
Clark and colleagues [23] | TNF-α antibody | 28 | 3/14 (21.4%) | 3/14 (21.4%) | MAP 90–110 mmHg |  |
Briegel and colleagues [17] | Stress dose hydrocortisone | 40 | 6/20 (30%) | 5/20 (25%) | MAP > 70 mmHg | PAOP 12–15 mmHg |
Rivers and colleagues [14] | Multifaceted early goal-directed therapy protocol | 263 | 70/133 (52.6) | 50/130 (38.4) | MAP ≥ 65 mmHg | CVP 8–12 mmHg, EGDT SVO2 ≥ 70% |
Cole and colleagues [13] | Continuous hemofiltration | 24 | 4/12 (33.3%) | 4/12 (33.3%) | MAP ≥ 70 mmHg |  |
Emet and colleagues [16] | N-acetyl-cysteine | 53 | 8/26 (30.7%) | 7/27 (25.9%) |  | CVP 4–8 mmHg |
Bakker and colleagues [20] | Nitric oxide synthase inhibitor | 312 | 75/155 (48.3%) | 72/155 (46.2%) | MAP ≥ 70 mmHg | CI ≥ 3 l/min/m2 |
Lopez and colleagues [21] | Nitric oxide synthase inhibitor | 797 | 174/358 (48.6%) | 259/439 (59%) | MAP 70–90 mmHg | CI ≥ 3 l/min/m2 |